Education
About Us
Working with TipRanks
Follow Us
Medifast (MED)
NYSE:MED
MED Stock Chart & Stats
$10.97
-$0.62(-3.78%)
At close: 4:00 PM EST
$10.97
-$0.62(-3.78%)
Day’s Range― - ―
52-Week Range$10.36 - $18.59
Previous CloseN/A
Volume160.90K
Average Volume (3M)253.83K
Market Cap
$121.34M
Enterprise Value-$11.00M
Total Cash (Recent Filing)$173.51M
Total Debt (Recent Filing)$12.26M
Price to Earnings (P/E)528.2
Beta0.42
Next Earnings
Feb 24, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding10,991,273
10 Day Avg. Volume357,235
30 Day Avg. Volume253,829
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)0.92
Price to Sales (P/S)0.32
P/FCF Ratio11.31
Enterprise Value/Market Cap-0.09
Enterprise Value/Revenue-0.03
Enterprise Value/Gross Profit-0.04
Enterprise Value/Ebitda-1.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.9
Revenue Forecast (FY)$384.80M
Medifast News
MED FAQ
What was Medifast’s price range in the past 12 months?
Medifast lowest stock price was $10.36 and its highest was $18.59 in the past 12 months.
What is Medifast’s market cap?
Medifast’s market cap is $121.34M.
When is Medifast’s upcoming earnings report date?
Medifast’s upcoming earnings report date is Feb 24, 2026 which is in 58 days.
How were Medifast’s earnings last quarter?
Medifast released its earnings results on Nov 03, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.36 by $0.15.
Is Medifast overvalued?
According to Wall Street analysts Medifast’s price is currently Overvalued.
Does Medifast pay dividends?
Medifast pays a Quarterly dividend of $1.65 which represents an annual dividend yield of N/A. See more information on Medifast dividends here
What is Medifast’s EPS estimate?
Medifast’s EPS estimate is -0.82.
How many shares outstanding does Medifast have?
Medifast has 10,991,273 shares outstanding.
What happened to Medifast’s price movement after its last earnings report?
Medifast reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.36. Following the earnings report the stock price went up 0.842%.
Which hedge fund is a major shareholder of Medifast?
Currently, no hedge funds are holding shares in MED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medifast Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
MED Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 294.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 5.1%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.83%
12-Months-Change
Fundamentals
Return on Equity
0.12%
Trailing 12-Months
Asset Growth
-7.91%
Trailing 12-Months
Company Description
Medifast
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland.
MED Company Deck
MED Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view of challenges and progress. While Medifast highlighted significant achievements in clinical research and a strong financial position, the company also faced substantial revenue declines and a decrease in active coaches. Despite the challenges, the company is optimistic about new product launches and strategic programs to stabilize and grow in the future.View all MED earnings summariesTechnical Analysis
Ownership Overview
4.71% Insiders
15.04% Mutual Funds
7.57% Other Institutional Investors
52.92% Public Companies and
Individual Investors